Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.
Virol Sin. 2024 Apr;39(2):218-227. doi: 10.1016/j.virs.2024.01.010. Epub 2024 Feb 3.
The SARS-CoV-2 Omicron variants are notorious for their transmissibility, but little is known about their subgenomic RNA (sgRNA) expression. This study applied RNA-seq to delineate the quantitative and qualitative profiles of canonical sgRNA of 118 respiratory samples collected from patients infected with Omicron BA.2 and compared with 338 patients infected with non-variant of concern (non-VOC)-D614G. A unique characteristic profile depicted by the relative abundance of 9 canonical sgRNAs was reproduced by both BA.2 and non-VOC-D614G regardless of host gender, age and presence of pneumonia. Remarkably, such profile was lost in samples with low viral load, suggesting a potential application of sgRNA pattern to indicate viral activity of individual patient at a specific time point. A characteristic qualitative profile of canonical sgRNAs was also reproduced by both BA.2 and non-VOC-D614G. The presence of a full set of canonical sgRNAs carried a coherent correlation with crude viral load (AUC = 0.91, 95% CI 0.88-0.94), and sgRNA ORF7b was identified to be the best surrogate marker allowing feasible routine application in characterizing the infection status of individual patient. Further potentials in using sgRNA as a target for vaccine and antiviral development are worth pursuing.
SARS-CoV-2 的奥密克戎变体以其传染性而臭名昭著,但人们对其亚基因组 RNA(sgRNA)的表达知之甚少。本研究应用 RNA-seq 描绘了从感染奥密克戎 BA.2 的患者中收集的 118 个呼吸道样本中 11 种规范 sgRNA 的定量和定性特征,并与 338 名感染非关注变体(non-VOC)-D614G 的患者进行了比较。BA.2 和非-VOC-D614G 无论宿主性别、年龄和是否存在肺炎,都复制了由 9 种规范 sgRNA 的相对丰度描绘的独特特征谱。值得注意的是,这种谱在病毒载量低的样本中丢失,这表明 sgRNA 模式可能具有指示个体患者在特定时间点病毒活性的应用潜力。BA.2 和非-VOC-D614G 也复制了规范 sgRNAs 的特征定性谱。规范 sgRNAs 的完整集的存在与粗病毒载量具有一致的相关性(AUC=0.91,95%CI 0.88-0.94),sgRNA ORF7b 被鉴定为最佳替代标志物,允许在个体患者的感染状态特征化中可行的常规应用。sgRNA 作为疫苗和抗病毒药物开发目标的进一步潜力值得探索。